论文部分内容阅读
目前已十分明确各种癌肿患者血清β_2-微球蛋白可以升高。本文旨在研究β_2-微球蛋白水平是否有助于泌尿系癌肿的生化监测.作者筛选了298例泌尿系癌肿患者。选择血清肌酐水平≤105μmol/L 的肾癌、膀胱癌和前列腺癌患者测定血清β_2-微球蛋白的水平。膀胱癌按癌肿结节和转移分期。35例已治的 T_1期膀胱癌及无肿瘤者血标本作对照组(正常值2.4mg/L)。5例晚期膀胱癌患者连续测定β_2-微球蛋白。结果膀胱癌患者常倾向于高血清β_2-微球蛋白,肿瘤期增高达15～57%,肿瘤大小和β_2-微球蛋白水平之间无明显关系。作单侧肾切除术的肾癌患者因血清肌酐水平普遍升高而妨碍用β_2-微球蛋白作为术后疾病进展的指标。与膀胱癌相反,前列腺癌尽管癌肿很大,但血清β_2-微球蛋白升高的病例很少。
It is now clear that serum β 2 -microglobulin levels can be elevated in various cancer patients. This article aims to investigate whether the level of β 2 -microglobulin is helpful for the biochemical monitoring of urinary cancer. The authors screened 298 patients with urinary cancer. Serum β2-microglobulin levels were measured in patients with renal, bladder, and prostate cancers with serum creatinine levels <105 μmol/L. Bladder cancer is classified by cancerous nodules and metastases. Thirty-five patients with T1 bladder cancer and those without tumor were treated with control group (normal value 2.4 mg/L). Continuous determination of β 2 -microglobulin in 5 patients with advanced bladder cancer. Results Bladder cancer patients often tended to high serum β 2 -microglobulin, and the tumor stage increased by 15 to 57%. There was no obvious relationship between tumor size and β 2 -microglobulin levels. Patients with kidney cancer undergoing unilateral nephrectomy are generally prevented from using β2-microglobulin as an indicator of postoperative disease progression due to the general increase in serum creatinine levels. In contrast to bladder cancer, there are few cases of elevated serum β 2 -microglobulin despite the large cancer.